Interest Rate Environment: Changes in interest rates can significantly affect funding costs for clinical-stage biotech companies, impacting their R&D budgets and the valuation of future revenue streams.

Biopharmaceutical Regulatory Landscape and Drug Pricing Policy: Regulatory hurdles, potential changes in drug pricing policies, and the efficiency of FDA approvals can influence market access and profitability of new drug candidates.

Clinical Trial Success and Pipeline Development: The progression and outcomes of ongoing clinical trials for Corvus's drug candidates, particularly in oncology and immunology, are critical drivers of investor confidence and future market potential.